Mersana therapeutics, inc. (MRSN)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
Cash flows from operating activities
Net income (loss)

-28,208

-64,257

-38,707

-13,700

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation

1,245

1,257

928

655

Loss on disposal of fixed assets

-

-20

-

-

Net amortization of premiums and discounts on investments

222

296

293

-

Stock-based compensation

4,872

3,884

1,422

668

Change in deferred rent

-

110

-159

102

Other non-cash items

-103

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-459

-325

-267

411

Prepaid expenses and other current assets

-2,179

1,690

1,200

245

Other assets

-

1,132

-60

60

Accounts payable

-3,110

7,375

1,335

-325

Accrued expenses

-3,569

5,431

3,562

1,726

Operating lease assets

-1,771

-

-

-

Operating lease liabilities

-1,883

-

-

-

Deferred revenue

-41,381

-6,243

-9,894

43,178

Net cash used in operating activities

-67,744

-55,216

-42,679

31,588

Cash flows from investing activities
Maturities of marketable securities

27,000

88,565

47,220

-

Purchase of marketable securities

53,688

-

145,701

-

Purchase of property and equipment

605

1,370

1,143

1,084

Net cash provided by investing activities

-27,293

87,195

-99,624

-1,084

Cash flows from financing activities
Net proceeds from offering of common stock

92,162

-

-

-

Proceeds from exercise of stock options

175

918

452

105

Proceeds from purchases of common stock under ESPP

489

146

-

-

Proceeds from issuance of debt, net of issuance costs

4,965

-

-

-

Payments under capital lease obligations

87

-

-

-

Net cash provided by (used in) financing activities

97,704

1,064

68,597

58,259

Increase (decrease) in cash, cash equivalents and restricted cash

2,667

33,043

-73,706

88,763

Supplemental disclosures of non-cash activities:
Fair value of common stock retired in exchange for issuance of common stock warrant

8,986

-

-

-

Conversion of preferred stock to common stock upon closing of initial public offering

-

-

94,450

-

Purchases of property and equipment in accounts payable and accrued expenses

-

317

35

414

Debt financing costs in accrued expenses

180

-

-

-

Cash paid for interest

132

-

-

-

Right-of-use assets obtained in exchange for operating lease liabilities

4,369

-

-

-

Right-of-use assets obtained in exchange for financing lease liabilities

429

-

-

-

Purchases of property and equipment reimbursed by landlord

-

-

-

356

Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606

-

-2,031

-

-

IPO
Net proceeds from initial public offering

-

-

67,420

-

Over allotment option
Net proceeds from initial public offering

-

-

725

-

Series B-1 convertible preferred stock
Net proceeds from sale of convertible preferred stock

-

-

-

25,272

Series C-1 convertible preferred stock
Net proceeds from sale of convertible preferred stock

-

-

-

32,882